Novo Nordisk Launches Dosage Study for Oral Semaglutide
MT Newswires Live
Aug 19
Novo Nordisk (NVO) has initiated a study to see how oral semaglutide, when taken in lower doses, impacts body weight in participants with excess body weight when compared to a placebo, a regulatory filing said Tuesday.
The primary endpoint aims to discern the optimal lower dose of oral semaglutide to treat overweight or obese patients, the filing said.
The filing said the OASIS 5 study began Aug. 12 and is recruiting an estimated 450 participants.
The study is estimated to be completed in April 2028.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.